Market News
Global Substance Abuse Treatment Market- Recent Developments
Acquisition and Partnership
- On November 29, 2023, World Health Organization (WHO) designates a new Collaborating Centre on Substance Use, Noncommunicable Disease and Policy Impact which will focus on reducing substance use as a means of reducing the burden imposed by noncommunicable diseases (NCDs).
- On May 23, 2023, Camurus announced that the US Food and Drug Administration (FDA) has approved Brixadi (buprenorphine) extended release injection for subcutaneous (SC) use, a weekly and monthly medication for the treatment of moderate to severe opioid use disorder (OUD), in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a daily buprenorphine product.
- On January 4, 2023, Tempero Bio, a clinical-stage biopharmaceutical company received approval from the U.S. FDA for its investigational new drug (IND) application for TMP-301, a lead candidate that is used for indication of treatment of cocaine use disorder.
- In January 2022, Pfizer Inc., one of the global pharmaceutical company, entered into a strategic partnership with Alex Therapeutics, a company providing digital health solutions. This collaboration is set to leverage Alex Therapeutics' AI-driven digital platform which integrates techniques from cognitive behavioral therapy (CBT) and acceptance and commitment therapy (ACT), to aid those battling nicotine addiction.
U.S.: 
U.K. : 
India : 
